Site Initiation Visit Completed
Phase I clinical trial site initiation completed for HG-CT-1 in relapsed/refractory AML; patient recruitment to follow.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals Successfully Completes the Site Initiation Visit of the First Clinical Site for Phase I Clinical Trial of HG-CT-1
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, is pleased to announce the successful completion of the Site Initiation Visit at the first clinical site for its Phase I clinical trial of HG-CT-1 (also known as HEMO-CAR-T). The Phase I clinical trial is designed as a dose escalation study to assess the safety of HG-CT-1 in adult patients with relapsed/refractory (R/R) acute myeloid leukaemia (AML).
Patient recruitment will begin once the clinical site provides final details to the Company's clinical trials manager, Prevail Infoworks.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"This step marks a significant milestone for the Company as we advance our lead asset, HG-CT-1, into clinical trials. This study represents our commitment to developing innovative therapies for patients with R/R AML, a condition with limited treatment options.
We are excited to see patient recruitment set to begin and take the next steps in assessing the safety and treatment potential of HEMO-CAR-T. We remain dedicated to delivering transformative therapies that address critical unmet medical needs."
About AML and CAR-T Therapy
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.